Johad Khoury
Postdoctoral AssociateAbout
Research
Publications
2025
Separation of telomere protection from length regulation by two different point mutations at amino acid 492 of RTEL1
Smoom R, May C, Lichtental D, Bar-Ness K, Rangel R, Khoury J, Nachmani D, Avrahami D, Ahangari F, Skordalakes E, Kaminski N, Kaestner K, Tzfati Y. Separation of telomere protection from length regulation by two different point mutations at amino acid 492 of RTEL1. Nucleic Acids Research 2025, 53: gkaf507. PMID: 40530700, PMCID: PMC12203905, DOI: 10.1093/nar/gkaf507.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAnimalsDisease Models, AnimalDNA DamageDNA HelicasesDyskeratosis CongenitaFetal Growth RetardationGrowth DisordersHematopoiesisHumansIntellectual DisabilityLimb Deformities, CongenitalLungMiceMicrocephalyPoint MutationTelomereTelomere HomeostasisX-Linked Intellectual DisabilityConceptsHoyeraal-Hreidarsson syndromeTelomere protectionLength regulationTelomere length regulationTelomere-related diseasesTelomere biology disordersDNA helicaseMouse genomeGenome stabilityMouse modelMouse telomeresAberrant hematopoiesisGenomic instabilityPoint mutationsHouse miceTelomeric DNA damageAnaphase bridgesRTEL1Amino acidsTelomereMechanistic rolesDNA damageMutationsIsoleucine mutationGenomeTicagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, Dobrecky-Mery I. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines 2025, 12: 13. PMID: 40407605, PMCID: PMC12194868, DOI: 10.3390/medicines12020013.Peer-Reviewed Original ResearchAcute coronary syndromeCoronary syndromeAntiplatelet drugsCardiovascular deathComposite endpoint of cardiovascular deathAdmitted with acute coronary syndromeEndpoint of cardiovascular deathTreated with ticagrelorTreated with prasugrelSingle-center studyRetrospective observational studyRecurrent cardiac eventsDual antiplatelet drugsReal-world treatmentPercutaneous coronary interventionBARC classificationSignificant bleedingPrasugrel groupPrimary endpointP2Y12 inhibitorsNo significant differenceACS patientsCardiac eventsComposite endpointPrasugrelEarly IPF Is Characterized by a Dramatic Shift of the Epithelial and Endothelial Populations Within the Alveolar Niche
Justet A, Adams T, Khoury J, Balayev A, Abu Hussein N, Schupp J, Zhao A, Manning E, Ahangari F, Yan X, Ravaglia C, Tomassetti S, Poletti V, Kaminski N. Early IPF Is Characterized by a Dramatic Shift of the Epithelial and Endothelial Populations Within the Alveolar Niche. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a7109-a7109. DOI: 10.1164/ajrccm.2025.211.abstracts.a7109.Peer-Reviewed Original ResearchThe Potential Role of GPR87 in the Development of Pulmonary Fibrosis
Khoury J, Ahangari F, Justet A, Adams T, Manning E, Mcdonough J, Anderson S, Nekola F, Beermann M, Bauer Y, Gomez J, Kaminski N. The Potential Role of GPR87 in the Development of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a7110-a7110. DOI: 10.1164/ajrccm.2025.211.abstracts.a7110.Peer-Reviewed Original ResearchEx-vivo Lung Tissue Culture Exhibits Spontaneous Generation and Maintenance of Fibrosis
Marti Munoz J, Khoury J, Ahangari F, Anderson S, Manning E, Velasco-Alzate K, Deiuliis G, Pandit A, Kaminski N. Ex-vivo Lung Tissue Culture Exhibits Spontaneous Generation and Maintenance of Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a4660-a4660. DOI: 10.1164/ajrccm.2025.211.abstracts.a4660.Peer-Reviewed Original ResearchApplying single cell profiling to assess drug anti fibrotic properties in the human precision cut lung slice model of fibrosis
Justet A, Mitash N, Pineda R, Adams T, Balayev A, Abu Hussein N, Ishizuka M, Kim H, Khoury J, Cala-García J, Ahangari F, Yan X, Kaminski N, Königshoff M. Applying single cell profiling to assess drug anti fibrotic properties in the human precision cut lung slice model of fibrosis. Revue Des Maladies Respiratoires 2025, 42: 223. DOI: 10.1016/j.rmr.2025.02.083.Peer-Reviewed Original ResearchAbnormal cell populationsAlveolar epithelial cellsTreated with drugsAnti-fibrotic propertiesSingle cell platformsSingle nuclear RNA sequencingLigand-receptor analysisPreclinical evidencePulmonary fibrosisBasaloid cellsFibrotic propertiesReceptor analysisFibrotic pathwaysCell signaturesClinical trialsProfibrotic genesAnti-fibroticFDA-approved drugsGene signatureAnimal modelsEpithelial cellsGene expression changesDay 5Drug efficacyCell profiles
2024
Applying single-cell profiling to assess drug anti-fibrotic properties in the human precision-cut lung slice model of fibrosis
Justet A, Mitash M, Raredon S, Pineda R, Adams T, Al Hussein N, Ishizuka M, Hahram K, Khoury J, Ahangari F, Xiting Y, Naftali K, Melanie K. Applying single-cell profiling to assess drug anti-fibrotic properties in the human precision-cut lung slice model of fibrosis. 2024, oa1896. DOI: 10.1183/13993003.congress-2024.oa1896.Peer-Reviewed Original ResearchToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024, 211: 91-102. PMID: 39189851, PMCID: PMC11755360, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelSingle-cell RNA-seq analysis of cell-cell communications in human lung reveals a novel role of VEGF-D in acute lung injury
Yuan Y, Sharma L, Tang W, Raredon M, Ahangari F, Khoury J, Wu D, Niklason L, Kaminski N. Single-cell RNA-seq analysis of cell-cell communications in human lung reveals a novel role of VEGF-D in acute lung injury. Physiology 2024, 39: 1314. DOI: 10.1152/physiol.2024.39.s1.1314.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisAcute lung injuryChronic obstructive pulmonary diseaseAcute respiratory distress syndromeAnalysis of cell-cell communicationVEGF-DMicrovascular nicheSingle-cell RNA-seqLung injury modelSingle-cell RNA-seq analysisLung injuryCell-cell communicationLigand-receptor pairsLPS-induced lung injury modelRNA-seqAdjacent cell typesPulmonary diseaseInjury modelHuman lung endothelial cellsBarrier functionImmune cell infiltrationTumor necrosis factor-aRespiratory distress syndromeLung vascular integrityGene expressionNebulizable Conjugates to Sustain Retention, Delivery, and Efficacy of Galectin-3 Inhibitory Drug TD139 in the Alveolar Space
Marti Munoz J, Khoury J, Ahangari F, Deiuliis G, Kaminski N, Pandit A. Nebulizable Conjugates to Sustain Retention, Delivery, and Efficacy of Galectin-3 Inhibitory Drug TD139 in the Alveolar Space. 2024, a3218-a3218. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3218.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
300 Cedar Street, Room 460S
New haven, CT 06519
United States